Treatment of active-phase Peyronie’s disease (PD) “remains a challenge for urologists,” according to a recent review of medical studies. Affecting an estimated 3% to 9% of men, Peyronie’s disease is a benign condition that causes plaques to form within the tunica albuginea of the penis. It’s exact cause is unknown. Symptoms of Peyronie’s disease include […]
Researchers have discovered a combination of compounds that may help in the treatment of Peyronie’s disease in its active phase, according to a recent study in European Urology. After testing 21 substances in an phenotypic screening assay and working with rat models, they determined that the combination of vardenafil [a phosphodiesterase type 5 (PDE5) inhibitor] […]
When diagnosing Peyronie’s disease, there are a number of factors to consider, including the degree of curvature, the size and characteristics of plaques, the presence of pain, and the ability to have an erection suitable for intercourse…
Unfortunately, some medical procedures can result in penile shortening. In a recent paper published by Sexual Medicine Reviews, researchers looked at various studies on penile size and the effects of surgical treatments for Peyronie’s disease, erectile dysfunction (ED), and prostate cancer.
Men with Peyronie’s disease could be at higher risk for certain types of cancer. A study involving over 1.7 million men found higher risk of stomach cancer, melanoma, and testicular cancer among men with Peyronie’s disease when compared to men with erectile dysfunction (ED).
New research in the Journal of Sexual Medicine reports that injections of collagenase Clostridium histolyticum (CCH) can be a safe and effective way to treat Peyronie’s disease in its acute phase.